ºÏ¹ÌÀÇ ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ½ÃÀå ±Ô¸ð´Â 2023³â 1¾ï 2,052¸¸ 7,140´Þ·¯¿¡¼ 2031³â¿¡´Â 2¾ï 4,510¸¸ 9,600´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2023-2031³â CAGR 9.3%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÁÖ¿ä ¿ä¾à-ºÏ¹ÌÀÇ ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ½ÃÀå ºÐ¼®
¸¸¼º ºÎºñµ¿¿°°ú °°Àº À̺ñÀÎÈİú ÁúȯÀÇ À¯º´·ü Áõ°¡´Â ij³ª´Ù¿¡¼ È¿°úÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Canadian Family Physician¿¡ µû¸£¸é, ºñ ºÎºñµ¿¿°Àº ÀϹÝÀûÀ̸ç ij³ª´Ù¿¡¼´Â ¼ºÀÎÀÇ ¾à 8¸í Áß 1¸íÀÌ °íÅëÀ» ¹Þ°í ÀÖ½À´Ï´Ù. Àα¸ÀÇ °í·ÉÈ¿Í À̺ñÀÎÈİúÀÇ °Ç° ¹®Á¦¿¡ ´ëÇÑ ÀÇ½Ä Áõ°¡´Â ÀÌ ³ª¶óÀÇ ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú¿¡ ÀÌÀÍÀ» °¡Á®¿Ô½À´Ï´Ù.
ºÏ¹ÌÀÇ ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ½ÃÀå-ºÎ¹®º° ºÐ¼® :
·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ºÐ¼®¿¡ ±â¿©ÇÑ ÁÖ¿ä ºÎ¹®Àº ·¹ÀÌÀú À¯Çü, ¼ö¼ú À¯Çü ¹× ÃÖÁ¾ »ç¿ëÀÚÀÔ´Ï´Ù.
·¹ÀÌÀú À¯Çüº°·Î, ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ½ÃÀåÀº CO2 ·¹ÀÌÀú, Nd:YAG ·¹ÀÌÀú, ´ÙÀÌ¿Àµå ·¹ÀÌÀú, û»ö ·¹ÀÌÀú, KTP ·¹ÀÌÀú, ¾Æ¸£°ï ·¹ÀÌÀú, ±âŸ ·¹ÀÌÀúÀÇ À¯Çü·Î ±¸ºÐµË´Ï´Ù. 2023³â¿¡´Â CO2 ·¹ÀÌÀú°¡ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¼ö¼ú À¯Çüº°·Î ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ½ÃÀåÀº ·¹ÀÌÀú ÈĵΠ¼ö¼ú, ·¹ÀÌÀú ³»½Ã°æ ºÎºñµ¿ ¼ö¼ú(LESS), ·¹ÀÌÀú Áö¿ø ±¸°³¼öÇü¼º¼ú(LAUP), ·¹ÀÌÀú¸¦ ÀÌ¿ëÇÑ °í¸· Àý°³¼ú, ·¹ÀÌÀú¸¦ ÀÌ¿ëÇÑ Æíµµ¼± ÀýÁ¦¼ú ¹× ¾Æµ¥³ëÀ̵å ÀýÁ¦¼ú, ·¹ÀÌÀú ºñ°©°³ ¼ö¼ú, °æ±¸° ·¹ÀÌÀú Çö¹Ì°æ ¼ö¼ú(TLM), ÄÚ ¼ö¼ú ¹× ±âŸ ¼ö¼ú À¯ÇüÀ¸·Î ³ª´¹´Ï´Ù. 2023³â¿¡´Â ·¹ÀÌÀú Áö¿ø Æíµµ¼± ÀýÁ¦¼ú°ú ¾Æµ¥³ëÀ̵å ÀýÁ¦¼ú ºÎ¹®ÀÌ ½ÃÀå¿¡¼ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ÃÖÁ¾ »ç¿ëÀÚº°·Î ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ½ÃÀåÀº º´¿ø, Àü¹® Ŭ¸®´Ð, °³¾÷ ÀÇ»ç ¹× ±âŸ ÃÖÁ¾ »ç¿ëÀÚ·Î ºÐ·ùµË´Ï´Ù. º´¿ø ¹× Àü¹® Ŭ¸®´Ð ºÎ¹®ÀÌ 2023³â¿¡ ½ÃÀå¿¡¼ ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
ºÏ¹ÌÀÇ ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ½ÃÀå-Àü¸Á
¸¸¼º ºÎºñµ¿¿°, ¼ö¸é ¹«È£Èí ÁõÈıº, û·Â »ó½Ç, µÎ°æºÎÀÇ °¢Á¾ Á¾¾ç µîÀÇ Áúº´ÀÌ ÈçÇØÁö°í ÀÖÀ¸¸ç, °í±Þ ¼ö¼ú °³ÀÔÀÌ ÇÊ¿äÇÕ´Ï´Ù. ·¹ÀÌÀú Áö¿ø ¼ö¼úÀº Àúħ½À¼ºÀ¸·Î ¼³µæ·Â ÀÖ´Â ¼Ö·ç¼ÇÀ» Á¦°øÇϸç, ½Å¼ÓÇÑ È¸º¹ ½Ã°£ ¹× ¼ö¼ú ÈÄ ºÒÆíÇÔÀ» ÁÙÀÌ´Â °ÍÀ» ¾à¼ÓÇÏ´Â ¼ö¼ú¿¡ ´ëÇÑ È¯ÀÚÀÇ ¼±È£µµ Áõ°¡¿Í ÀÏÄ¡ÇÕ´Ï´Ù. 2024³â Rhinology ÀâÁö¿¡ °ÔÀçµÈ ³í¹®¿¡ µû¸£¸é ¸¸¼º ÄÚ ºÎºñ°¿°ÀÇ À¯º´·üÀº 5-12%·Î, ÀÌ Áß ºñ¿ëÁ¾Àº ¼¼°è¿¡¼ 20%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù.
¼¼°è Àα¸ÀÇ °í·ÉÈ¿¡ µû¶ó À̺ñÀÎÈİú(ie, ear, nose, and throat) Áúȯ¿¡ ´ëÇÑ È¿°úÀûÀ̰í Çõ½ÅÀûÀÎ Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ È¯°æ ¿äÀÎÀº À̺ñÀÎÈİú °ü·Ã ÁúȯÀ» ´õ¿í ¾ÇȽÃŵ´Ï´Ù. National Council on Aging, Inc.¿¡ µû¸£¸é ³Ã»Àº 12¼¼ ÀÌ»óÀÇ ¹Ì±¹ÀÎ ¾à 6,070¸¸ ¸í¿¡ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. 20¼¼ ÀÌ»ó ¹Ì±¹ ¼ºÀÎÀÇ ¾à 15.5%(4,410¸¸ ¸í)°¡ ³Ã»ÀÔ´Ï´Ù. ¶ÇÇÑ, À̺ñÀÎÈİú ÁúȯÀÇ À¯º´·ü Áõ°¡´Â Á¶±â Áø´Ü°ú Ä¡·áÀÇ Á߿伺¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡¸¦ ¼ö¹ÝÇÕ´Ï´Ù. ȯÀÚ´Â °Ç°¿¡ ´ëÇÑ ¼±Åÿ¡ ´ëÇÑ Á¤º¸¸¦ ´õ ¾ò°Ô µÇ¾ú°í, ¾ÕÀ¸·Î Áøº¸µÈ Ä¡·á¹ýÀ» ¿ä±¸ÇÏ°Ô µÇ¾ú±â ¶§¹®¿¡ À̺ñÀÎÈİú Ä¡·áÀÇ »óȲÀº ±Ùº»ÀûÀ¸·Î º¯ÈÇϰí ÀÖ½À´Ï´Ù. ÀÌ µ¿ÇâÀº À̺ñÀÎÈİú ÁúȯÀÇ Á¶±â ¹ß°ßÀ» ¿ëÀÌÇÏ°Ô ÇÏ´Â Áø´Ü µµ±¸ÀÇ ±â¼úÀû Áøº¸¿¡ ÀÇÇØ µÞ¹ÞħµË´Ï´Ù. µû¶ó¼ ȯÀÚ°¡ Áø´ÜÇÏÀÚ¸¶ÀÚ ¿Ü°úÀû °³ÀÔÀÌ ÇÊ¿äÇÒ °¡´É¼ºÀÌ ³ô¾ÆÁ® ·¹ÀÌÀú¸¦ ÀÌ¿ëÇÑ ¼ö¼úÀÇ °Ç¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù.
ºÏ¹ÌÀÇ ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ½ÃÀå-±¹°¡º° ÀλçÀÌÆ®
±¹°¡º°·Î º¸¸é ºÏ¹ÌÀÇ ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼úÀº ¹Ì±¹, ij³ª´Ù, ¸ß½ÃÄÚ·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ¹Ì±¹Àº 2023³â ÃÖ´ë Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
Sylvester Comprehensive Cancer Center´Â ÈĵξÏÀÇ °¡Àå ÈçÇÑ À¯ÇüÀÎ ¼º¹®¾ÏÀÇ Á¶±â Ä¡·á¿¡ 445nm û»ö ·¹ÀÌÀú¸¦ ¹Ì±¹¿¡¼ óÀ½ »ç¿ëÇß½À´Ï´Ù. ¹Ì±¹¿¡´Â ¾à 2,000¸íÀÇ À̺ñ°ú Àǻ簡 ÀÖ½À´Ï´Ù. ±× ¸¹Àº »ç¶÷µéÀÌ 532nm ·¹ÀÌÀú ½Ã½ºÅÛÀ» »ç¿ëÇÏ¿© °í¸· ÀýÁ¦¼ú°ú °í¸· Àý°³¼úÀ» ¼öÇàÇÏ¿© ƯÁ¤ ³Ã»À» °³¼±ÇÕ´Ï´Ù. ¹Ì±¹¿¡¼´Â FDA°¡ ½ÂÀÎÇÑ À̺ñÀÎÈİú¿ë ·¹ÀÌÀú Àåºñ, ƯÈ÷ CO2 ·¹ÀÌÀú Àåºñ°¡ Á¤È®µµ¿Í ÁÖº¯ Á¶Á÷¿¡ ´ëÇÑ ¿ ¼Õ»óÀÌ Àû±â ¶§¹®¿¡ ¾Æµ¥³ëÀ̵å ÀýÁ¦¼ú ¹× ÈĵΠ¼ö¼ú°ú °°Àº Ä¡·á¿¡ ³Î¸® »ç¿ëµË´Ï´Ù. °Ô´Ù°¡ Nd:YAG ·¹ÀÌÀú ½Ã½ºÅÛÀº ´ÙÀÌ¿Àµå ·¹ÀÌÀú·Î, ºñÆóÀÇ Ä¡·á³ª ·¹ÀÌÀú Áö¿ø¿¡ ÀÇÇÑ ±¸°³¼ö ¼ºÇü¼ú µî¿¡ ÀϹÝÀûÀ¸·Î »ç¿ëµÇ°í ÀÖ½À´Ï´Ù. ¹Ì±¹ ½ÄǰÀǾ౹Àº ¶ÇÇÑ BIOLASEÀÇ EPIC 10 ¿¬Á¶Á÷ ·¹ÀÌÀú¸¦ À̺ñÀÎÈİú ¼ö¼ú¿¡ »ç¿ëÇÏ´Â °ÍÀ» Çã¿ëÇÕ´Ï´Ù. FDA ÀÎÁõ ·¹ÀÌÀú¸¦ ä¿ëÇÏ´Â ÀÇ·á½Ã¼³ÀÌ ´Ã¾î³²¿¡ µû¶ó ȸº¹ ½Ã°£ ´ÜÃà°ú Ä¡·á Á¤È®¼º Çâ»óÀ¸·Î ȯÀÚ °á°ú°¡ °³¼±µÉ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. FDA´Â ÀÌ·¯ÇÑ Àåºñ¸¦ ½ÂÀÎÇÏ´Â °ÍÀÌ ¸Å¿ì Áß¿äÇϸç, ¾ö°ÝÇÑ ¾ÈÀü¼º°ú È¿´É ±âÁØÀ» ÃæÁ·Çϰí ÀÇ·á ¼ºñ½º Á¦°ø¾÷ü¿Í ȯÀÚÀÇ ½Å·Ú¸¦ Á¶¼ºÇÕ´Ï´Ù.
ºÏ¹ÌÀÇ ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ½ÃÀå - ±â¾÷ ÇÁ·ÎÆÄÀÏ
ÀÌ ½ÃÀå¿¡¼ »ç¾÷À» Àü°³ÇÏ´Â ÁÖ¿ä ±â¾÷À¸·Î´Â biolitec AG(Biolitec), Iridex Corporation, Medence, Dimed Laser Technology Co., Ltd., intros Medical Laser GmbH, ARC Laser GmbH, LightScalpel, GIGAAMEDICAL, INTERmedic ARFRAN, Limmer Laser GmbH, Qolight Medical Laser, Sisram Medical Ltd. µîÀÌ ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¾÷µéÀº ¼ÒºñÀڵ鿡°Ô Çõ½ÅÀûÀÎ Á¦Ç°À» Á¦°øÇÏ°í ½ÃÀå Á¡À¯À²À» È®´ëÇϱâ À§ÇØ »ç¾÷ È®´ë, Á¦Ç° Çõ½Å, M&A µî ´Ù¾çÇÑ Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù.
À¯·´ÀÇ ·¹ÀÌÀú º¸Á¶ À̺ñÀÎÈİú ¼ö¼ú ½ÃÀå-ºÐ¼® ±â¹ý :
º» º¸°í¼¿¡¼ ¼Ò°³ÇÏ´Â µ¥ÀÌÅÍÀÇ ¼öÁý ¹× ºÐ¼®¿¡´Â ´ÙÀ½°ú °°Àº Á¶»ç ±â¹ýÀ» ä¿ëÇϰí ÀÖ½À´Ï´Ù.
2Â÷ Á¶»çÀÇ Á¶»ç °úÁ¤´Â °¢ ½ÃÀåÀÇ ÁúÀû ¹× ¾çÀû µ¥ÀÌÅ͸¦ ¼öÁýÇϱâ À§ÇØ »ç³»¿ÜÀÇ Ãâó¸¦ Ȱ¿ëÇÑ Á¾ÇÕÀûÀÎ 2Â÷ Á¶»ç·Î ½ÃÀ۵˴ϴÙ. ÀϹÝÀûÀ¸·Î ÂüÁ¶µÇ´Â 2Â÷ Á¶»ç ¼Ò½º´Â ´ÙÀ½°ú °°Áö¸¸, ÀÌ¿¡ ÇÑÁ¤µÇ´Â °ÍÀº ¾Æ´Õ´Ï´Ù.
±â¾÷ À¥»çÀÌÆ®, ¿¬·Ê º¸°í¼, À繫 Á¦Ç¥, ºê·ÎÄ¿ ºÐ¼®, ÅõÀÚÀÚ ÇÁ·¹Á¨Å×À̼Ç, »ê¾÷ Àü¹®Áö, ±âŸ °ü·Ã ÃâÆÇ¹° Á¤ºÎ ¹®¼, Åë°è µ¥ÀÌÅͺ£À̽º, ½ÃÀå º¸°í¼ ´º½º ±â»ç, º¸µµ ÀÚ·á, À¥ ij½ºÆ®. ±×·¯³ª ±â¾÷ ÇÁ·ÎÆÄÀÏ¿¡ Æ÷ÇÔµÈ ¸ðµç À繫 µ¥ÀÌÅÍ´Â ´Þ·¯·Î ÅëÇյ˴ϴÙ. ´Ù¸¥ ÅëÈ·Î º¸°íµÈ ±â¾÷ÀÇ ¼öÄ¡´Â ÇØ´ç ¿¬µµÀÇ °ü·Ã ȯÀ²À» »ç¿ëÇÏ¿© ´Þ·¯·Î ȯ»êµË´Ï´Ù.
1Â÷ Á¶»ç : Insight Partners´Â µ¥ÀÌÅÍ ºÐ¼®À» °ËÁõÇÏ°í ±ÍÁßÇÑ Áö½ÄÀ» ¾ò±â À§ÇØ ¸Å³â ¾÷°è ÀÌÇØ°ü°èÀÚ ¹× Àü¹®°¡µé¿¡°Ô »ó´ç¼öÀÇ 1Â÷ ÀÎÅͺ並 ½Ç½ÃÇß½À´Ï´Ù. ÀÌ·¯ÇÑ Á¶»ç´Â ´ÙÀ½À» ¸ñÀûÀ¸·Î ÇÕ´Ï´Ù.
2Â÷ Á¶»ç °á°ú¸¦ °ËÁõÇÏ°í °³¼±ÇÕ´Ï´Ù. ºÐ¼®ÆÀÀÇ Àü¹®Áö½Ä°ú ½ÃÀå ÀÌÇØ¸¦ ±í°Ô ÇÕ´Ï´Ù. ½ÃÀå ±Ô¸ð, µ¿Çâ, ¼ºÀå ÆÐÅÏ, °æÀï ¿ªÇÐ, ¹Ì·¡ Àü¸Á¿¡ ´ëÇÑ ÀλçÀÌÆ®¸¦ ¾ò½À´Ï´Ù. 1Â÷ ¼³¹®Á¶»ç´Â ´Ù¾çÇÑ ½ÃÀå, Ä«Å×°í¸®, ºÎ¹® ¹× ÇÏÀ§ ºÎ¹®À» ´ë»óÀ¸·Î Çϸç, À̸ÞÀÏÀ» ÅëÇÑ »óÈ£ÀÛ¿ë ¹× ÀüÈ ÀÎÅͺ信¼ ½Ç½ÃÇÕ´Ï´Ù. Âü°¡ÀÚ´Â ÀϹÝÀûÀ¸·Î ´ÙÀ½°ú °°½À´Ï´Ù.
¾÷°è ÀÌÇØ°ü°èÀÚ(ºÎ»çÀå, »ç¾÷°³¹ß ¸Å´ÏÀú, ¸¶ÄÏ ÀÎÅÚ¸®Àü½º ¸Å´ÏÀú, ±¹³» ¿µ¾÷ ¸Å´ÏÀú), ¾÷°è °íÀ¯ÀÇ Àü¹® Áö½ÄÀ» °¡Áø ¿ÜºÎ Àü¹®°¡(Æò°¡ Àü¹®°¡, ¸®¼Ä¡ ¾Ö³Î¸®½ºÆ®, ±¹³» ¿µ¾÷ ¸Å´ÏÀú, KOL(Key Opinion Leader))
The North America Laser-Assisted ENT Surgery Market size is expected to reach US$ 2,45,109.60 thousand by 2031 from US$ 1,20,527.14 thousand in 2023. The market is estimated to record a CAGR of 9.3% from 2023 to 2031.
Executive Summary and North America Laser-Assisted ENT Surgery Market Analysis:
The rising prevalence of ENT disorders, such as chronic sinusitis, is propelling the demand for effective treatment options in Canada. For instance, according to Canadian Family Physician, rhinosinusitis is common, afflicting approximately 1 in 8 adults in Canada. Population aging and increasing awareness regarding ENT health issues benefit the laser-assisted ENT surgery market in the country.
North America Laser-Assisted ENT Surgery Market Segmentation Analysis:
Key segments that contributed to the derivation of the laser-assisted ENT surgery market analysis are laser type, surgery type, and end user.
By laser type, the laser-assisted ENT surgery market is segmented into CO2 laser, Nd:YAG laser, diode laser, blue laser, KTP laser, argon laser, and other laser types. The CO2 laser held the largest share of the market in 2023.
In terms of surgery type, the laser-assisted ENT surgery market is divided into laser laryngeal surgery, laser endoscopic sinus surgery (less), laser-assisted uvulopalatoplasty (LAUP), laser-assisted stapedotomy, laser-assisted tonsillectomy and adenoidectomy, laser turbinate reduction, transoral laser microsurgery (TLM), nasal surgery, and other surgery types. The laser-assisted tonsillectomy and adenoidectomy segment held the largest share of the market in 2023.
Based on end user, the laser-assisted ENT surgery market is categorized into hospitals and specialty clinics, physician office, and other end-users. The hospitals and specialty clinics segment held the largest share of the market in 2023.
North America Laser-Assisted ENT Surgery Market Outlook
Conditions such as chronic sinusitis, sleep apnea, hearing loss, and various tumors of the head and neck are becoming more common, necessitating advanced surgical interventions. Laser-assisted surgeries offer a compelling solution due to their minimally invasive nature, which aligns with the growing preference among patients for procedures that promise quick recovery times and less postoperative discomfort. According to an article published in Rhinology in 2024, the prevalence range of chronic rhinosinusitis is 5-12%; from this, 20% have nasal polyps worldwide.
As the global population ages, the demand for effective and innovative treatment options for ENT (i.e., ear, nose, and throat) disorders surges in tandem. Also, environmental factors further worsen ENT-related conditions. According to the National Council on Aging, Inc., hearing loss affects about 60.7 million Americans aged 12 and older. About 15.5% (44.1 million) of American adults aged 20 and older have hearing loss. Further, the increasing prevalence of ENT disorders is accompanied by a heightened awareness of the importance of early diagnosis and treatment. As patients are more informed than ever about their health options, they willingly seek advanced therapies, thereby fundamentally reshaping the landscape of otolaryngological treatments. This trend is bolstered by technological advancements in diagnostic tools, which facilitate earlier detection of ENT conditions. Thus, as soon as patients are diagnosed, the likelihood of requiring surgical intervention increases, propelling the number of laser-assisted surgeries.
North America Laser-Assisted ENT Surgery Market Country Insights
Based on country, the North America laser-assisted ENT surgery market comprises the US, Canada, and Mexico. The US held the largest share in 2023.
The Sylvester Comprehensive Cancer Center was the first in the US to use the 445-nm blue laser for early glottic cancer treatment, the most common type of laryngeal cancer. There are approximately 2,000 otologists in the US. Many of them use 532-nm laser systems to perform stapedectomy and stapedotomy procedures to correct certain types of hearing loss. In the US, several FDA-approved ENT laser devices, notably CO2 laser devices, are widely used in procedures such as adenoidectomy and laryngeal surgery due to their precision and minimal thermal damage to surrounding tissues. Further, Nd: YAG laser systems are diode lasers that are commonly used to treat conditions such as nasal obstruction and perform laser-assisted uvulopalatoplasty. The US Food and Drug Administration has also cleared BIOLASE's EPIC 10 soft-tissue lasers for ENT surgical procedures. As more healthcare facilities adopt FDA-approved lasers, patient outcomes are likely to improve through reduced recovery times and enhanced procedural accuracy. The FDA's approval of these devices is crucial, ensuring they meet stringent safety and efficacy standards and fostering confidence among healthcare providers and patients.
North America Laser-Assisted ENT Surgery Market Company Profiles
Some of the key players operating in the market include biolitec AG (Biolitec); Iridex Corporation; Medency; Dimed Laser Technology Co., Ltd.; intros Medical Laser GmbH; ARC Laser GmbH; LightScalpel; GIGAAMEDICAL; INTERmedic ARFRAN; Limmer Laser GmbH; Qolight Medical Laser; and Sisram Medical Ltd., among others. These players are adopting various strategies such as expansion, product innovation, and mergers and acquisitions to provide innovative products to their consumers and increase their market share.
North America Laser-Assisted ENT Surgery Market Research Methodology :
The following methodology has been followed for the collection and analysis of data presented in this report:
Secondary Research The research process begins with comprehensive secondary research, utilizing both internal and external sources to gather qualitative and quantitative data for each market. Commonly referenced secondary research sources include, but are not limited to:
Company websites , annual reports, financial statements, broker analyses, and investor presentations. Industry trade journals and other relevant publications. Government documents , statistical databases, and market reports. News articles , press releases, and webcasts specific to companies operating in the market. Note: All financial data included in the Company Profiles section has been standardized to USD. For companies reporting in other currencies, figures have been converted to USD using the relevant exchange rates for the corresponding year.
Primary Research The Insight Partners' conducts a significant number of primary interviews each year with industry stakeholders and experts to validate its data analysis, and gain valuable insights. These research interviews are designed to:
Validate and refine findings from secondary research. Enhance the expertise and market understanding of the analysis team. Gain insights into market size, trends, growth patterns, competitive dynamics, and future prospects. Primary research is conducted via email interactions and telephone interviews, encompassing various markets, categories, segments, and sub-segments across different regions. Participants typically include:
Industry stakeholders : Vice Presidents, business development managers, market intelligence managers, and national sales managers External experts : Valuation specialists, research analysts, and key opinion leaders with industry-specific expertise